GLP-1 drugs 'may limit binge eating'

By the Editorial Team · Wednesday, July 15, 2026

Researchers at University College London found that weight-loss drugs known as GLP-1 receptor agonists may moderately reduce binge-eating episodes in individuals with binge-eating disorder. While these findings suggest a new therapeutic avenue, further clinical trials are needed to confirm their safety and effectiveness for this condition.

Weight-loss medications classified as GLP-1 receptor agonists may offer a potential treatment for individuals with binge-eating disorder, according to new research. The study, led by researchers at University College London and published in eClinicalMedicine, examined data from 8,069 individuals to assess the effects of GLP-1 drugs such as Wegovy and Mounjaro on binge eating behaviors.

Binge-eating disorder, which affects an estimated 17 million people worldwide, is characterized by recurrent episodes of consuming unusually large amounts of food accompanied by a sense of loss of control. Current treatment options include psychotherapy and certain medications, but effective therapies remain limited.

The analysis found that participants who used GLP-1 drugs reported moderate reductions in binge-eating episodes. These medications, originally developed for weight management and diabetes, work by influencing appetite regulation and satiety signals in the brain, which could explain their impact on binge-eating behaviors.

Despite these promising findings, the authors emphasize that available evidence is still preliminary. They called for comprehensive clinical trials to rigorously evaluate the efficacy and safety of GLP-1 receptor agonists specifically for binge-eating disorder. Such trials would help determine whether these drugs could become a viable treatment option beyond their current use.

Further research is also necessary to better understand the mechanisms by which GLP-1 drugs may affect eating behaviors and to identify which patient groups might benefit most. Given the substantial global burden of binge-eating disorder, new interventions could address a significant unmet need in mental health and obesity care.

In summary, while initial findings suggest that GLP-1 receptor agonists might help reduce binge eating, definitive conclusions require confirmation through controlled clinical studies. The potential for these drugs to expand treatment options offers a hopeful avenue for those affected by this challenging condition.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.